Thiago Prudêncio/SOPA Images/LightRocket via Getty Images
- J&J asked Pfizer, Moderna, and AstraZeneca to join a study into the potential risk of blood clots, The Wall Street Journal reported.
- Only AstraZeneca agreed, The Journal reported Friday.
- Pfizer and Moderna execs reportedly said their vaccines were safe.
- See more stories on Insider's business page.
Johnson & Johnson privately contacted other drugmakers producing COVID-19 vaccines to join a study into the potential risk of blood clots, but Pfizer and Moderna refused, The Wall Street Journal reported Friday, citing people familiar with the matter.
J&J contacted Pfizer, Moderna, and AstraZeneca to join the study, but only AstraZeneca agreed, The Journal reported.
Executives at Pfizer and Moderna said their vaccines were safe and that they didn't see the need to duplicate ongoing efforts to look for clotting cases, The Journal reported.
Insider has contacted all four companies for comment.
The US on Tuesday paused the rollout of the J&J vaccine whilst the Centers for Disease Control and Prevention (CDC), figures out whether J&J's vaccine caused blood clots in six people who had received the shot. US officials said their decision was made out of an "abundance of caution."
AstraZeneca's vaccine rollout in Europe was recently stunted over rare clotting concerns as well. The European Medicines Agency last week listed unusual blood clots with low platelets as a very rare side effect of the AstraZeneca vaccine. The agency said that the benefits of the shot outweigh the risks.
As Insider's Aria Bendix has reported, both the AstraZeneca and J&J shots use the same technology, but it is not yet clear if their clotting issues were related.
J&J's vaccine comes in a single dose, while the other three company's vaccines come in two shots.
This is a developing story. Please check back for more updates.
Dit artikel is oorspronkelijk verschenen op z24.nl